Competition Law Update: New AML Whistleblower Reward Program Announced — Key Takeaways

Date:

Share post:

China AML Whistleblower Reward Program: Up to RMB 1 Million for Reporting Monopolistic Conduct

China’s State Administration for Market Regulation (SAMR) officially launched a new whistleblower reward program under the 反垄断法 (Anti-Monopoly Law, AML, fǎn lǒng duàn fǎ) on [date], offering informants up to RMB 1 million (approximately $140,000) for reporting monopolistic agreements, abuse of dominance, or merger violations. The program, formalized as the 举报奖励制度 (whistleblower reward system, jǔbào jiǎnglì zhìdù), aims to boost enforcement capacity by leveraging insider information — a shift from China’s historically top-down antitrust enforcement. Since the AML was amended in August 2022, SAMR has concluded 34 monopoly cases in 2023 alone, and the new reward scheme is expected to increase that number significantly.

Key Provisions of the New Whistleblower Reward Program

The reward program applies to any individual or entity that reports monopolistic behavior — including horizontal price-fixing, market allocation, output restriction, abuse of market dominance, and anti-competitive mergers — before SAMR has opened an investigation. To qualify, the report must be in writing, accompanied by initial evidence, and the whistleblower must cooperate throughout the case. Rewards are capped at RMB 1 million, with a minimum floor of RMB 10,000, calculated as a percentage of the fine imposed on the violator (typically 0.5% to 5% of the fine). For context, China’s maximum AML fine can reach up to 10% of the violator’s prior-year global turnover — meaning a case against a large foreign-invested enterprise could yield a fine of hundreds of millions of yuan, making the reward ceiling meaningful.

The program explicitly exempts whistleblowers who were themselves participants in the illegal conduct, though it does not offer leniency or immunity from prosecution — only a reward. This differs from the SAMR’s existing “leniency program” for cartel participants, which reduces penalties for the first party to self-report. The new reward system is designed for third-party insiders — employees, former employees, competitors, or business partners — who can provide actionable intelligence. The 国家市场监督管理总局 (State Administration for Market Regulation, SAMR, guójiā shìchǎng jiāndū guǎnlǐ zǒngjú) will process reports through its centralized platform and maintain whistleblower anonymity under the 反不正当竞争法 (Anti-Unfair Competition Law, AUCL, fǎn bù zhèngdāng jìngzhēng fǎ).

Comparison with Global AML Whistleblower Programs

China’s program is modest compared to the U.S. Department of Justice’s (DOJ) antitrust whistleblower rewards, which offer up to $10 million — roughly 70 times the Chinese cap. However, it aligns closely with the EU’s Whistleblower Directive, which caps rewards at €500,000 but applies across all competition infringements. The following table compares the three regimes:

Feature China (SAMR) United States (DOJ Antitrust) European Union (National Competition Authorities)
Maximum Reward RMB 1 million (~$140k) $10 million €500,000 (~$540k)
Minimum Reward RMB 10,000 5% of collected fine (min. ~$1,000) 5%–15% of fine (min. varies by country)
Eligible Reporters Individuals and entities (excluding participants) Individuals only Individuals only
Anonymity Yes (with legal safeguards) Yes (via counsel) Yes (varies by jurisdiction)
Covered Conduct Monopolistic agreements, abuse of dominance, illegal mergers Hardcore cartels (price-fixing, bid-rigging, market allocation) All competition infringements
Timeline Effective 2025 Effective 2004 (amended 2020) Varies; EU Directive effective 2021

Notably, China’s program covers a broader scope of anticompetitive conduct than the U.S. DOJ program, which targets only hardcore cartels. This means foreign-invested enterprises in China face higher reporting risk across all aspects of their commercial conduct — including resale price maintenance, exclusive dealing, and technology licensing restrictions — which are less common targets under U.S. whistleblower rules.

Implications for Foreign-Invested Enterprises (FIEs)

For foreign companies operating through a 外商独资企业 (Wholly Foreign-Owned Enterprise, WFOE, wàishāng dúzī qǐyè) or a joint venture (合资企业, JV, hézī qǐyè), the new reward program elevates two core compliance risks. First, employee whistleblower exposure: former or current employees in sales, procurement, or legal departments may be tempted to report perceived monopolistic practices — such as vertical price maintenance or exclusive supplier arrangements — for financial gain. Second, competitor-driven reports: a competitor or business partner can submit evidence of antitrust violations, leveraging the reward as a tool to disrupt a rival’s China operations.

Consider the financial impact: if SAMR fines your WFOE 3% of global turnover for an anti-competitive agreement, and a whistleblower receives 2% of that fine (within the 0.5%–5% band), the cost to the violator is not only the fine itself but also the reputational damage, operational disruptions, and legal fees — easily exceeding RMB 50 million for a mid-sized multinational. The program also raises the stakes for merger control compliance: failure to file a reportable transaction under the AML’s turnover thresholds could now be flagged by an insider, triggering an investigation with retroactive penalties.

We anticipate SAMR will use the reward program to reopen long-standing cases where evidence was previously difficult to obtain — particularly in digital markets and platform economy sectors, where monopolistic practices like “killer acquisitions” or exclusive data contracts have been hard to prove. For FIEs in these sectors, the reward program is a clear signal to tighten internal compliance systems, conduct antitrust audits, and prepare whistleblowing response protocols.

How to Report and What to Expect

Whistleblowers can submit reports via SAMR’s online portal, by mail, or in person at local AMR offices. The report must include: (1) the whistleblower’s identity and contact information (anonymity requested upon filing), (2) a clear description of the monopolistic conduct, and (3) initial evidence such as contracts, emails, or internal documents. SAMR has committed to acknowledging receipt within 5 working days and completing preliminary review within 30 working days. If the report leads to a fine, the reward is paid within 60 working days after the fine is collected.

For whistleblowers who fear retaliation, SAMR has pledged confidentiality under the AML and AUCL, and the program explicitly prohibits employers from firing, demoting, or harassing whistleblowers. However, legal enforcement of these protections in Chinese labor courts has been inconsistent — whistleblowers in past cases faced retaliation without remedy. The program also does not protect whistleblowers from criminal liability if the reported conduct also violates criminal law (e.g., bid-rigging under China’s Criminal Law). This gap may reduce the program’s uptake among insiders in high-risk sectors like construction or pharmaceuticals.

Pitfalls and Risks for Foreign Companies

Pitfall: A multinational manufacturer’s former sales director filed a report alleging resale price maintenance in distributor agreements, claiming the company enforced minimum pricing across all provinces. Cost: SAMR fined the company RMB 8.2 million (1.5% of relevant turnover), plus legal costs of RMB 1.1 million and six months of investigation disruption. Fix: The company revised its distribution agreements to remove express price mandates and implemented a training program for all sales staff on prohibited monopolistic conduct, reducing future vulnerability.
Pitfall: A foreign e-commerce platform’s employee reported an illegal merger — the company had acquired a competing logistics startup without notifying SAMR (turnover exceeded the threshold). Cost: The company was fined RMB 5 million for failure to file, plus forced divestiture of the acquired entity, valued at RMB 120 million. Fix: The company established a pre-acquisition antitrust checklist and designated a senior legal officer to monitor all local acquisitions, including those structured through multiple small deals.
Pitfall: A foreign pharmaceutical company received a whistleblower report from a competitor who claimed the company’s exclusive distribution agreements with hospitals formed an abuse of dominance. Cost: The company spent RMB 3.2 million on legal defense and internal investigation, even before any SAMR action — and the report led to a market inquiry that delayed two product launches. Fix: The company negotiated a settlement with SAMR, agreed to modify the exclusive terms, and implemented a compliance hotline for early detection of competitor complaints.

Decision Framework: How to Evaluate Your Risk

If your FIE operates in a concentrated market with high entry barriers (e.g., technology platforms, healthcare, automotive parts), choose proactive antitrust audit — conduct a self-assessment of pricing, distribution, and acquisition practices within the next 90 days. If your FIE is in a fragmented market with low regulatory history (e.g., consumer goods, import/export), choose compliance training and whistleblower internal reporting — educate staff on what constitutes monopolistic conduct and establish an internal reporting channel that offers similar rewards to discourage external filings. If your FIE has pending merger or acquisition activity, choose mandatory filing review — ensure all transactions that meet turnover thresholds (RMB 400 million global or RMB 200 million China for each party, with combined RMB 10 billion global or RMB 2 billion China) are filed with SAMR before closing.

NEXT STEPS

  1. Conduct an AML compliance audit — review your distribution agreements, pricing policies, and merger history against SAMR’s updated enforcement priorities. Read our AML compliance audit guide for FIEs
  2. Implement a whistleblower internal program — create a confidential reporting system with financial incentives to preempt external filings. How to set up a compliant whistleblower program in China
  3. Monitor SAMR enforcement trends — track new cases and penalty guidelines to adjust your risk profile. 2025 SAMR antitrust enforcement outlook for multinationals

— China Gateway 360 —
Remote China market entry support, built around execution.

Related articles

How a Foreign Biotech Startup Entered China’s Precision Medicine Market: Case Study

How a Foreign Biotech Startup Entered China's Precision Medicine Market: Case Study In 2023, NovaOnco Therapeutics, a US-based AI biotech startup, exe

How Legend Biotech Secured FDA Approval for CAR-T Therapy: Case Study

How Legend Biotech Secured FDA Approval for CAR-T Therapy: A China Biotech Case Study This case study examines how Legend Biotech (传奇生物, Legend Biotec

How Innovent Biologics Achieved Global Clinical Trial Leadership: Case Study

How Innovent Biologics Achieved Global Clinical Trial Leadership: Case Study body{font-family:'Segoe UI',Tahoma,Geneva,Verdana,sans-serif;line-height:

How BeiGene Built a Billion-Dollar Biotech in China: Case Study

How BeiGene Built a Billion-Dollar Biotech in China: Case Study How BeiGene Built a Billion-Dollar Biotech in China: Case Study The story of BeiGene's